10-Q: ProAssurance Q3 Earnings Plunge Amid Merger Costs, Weak Underwriting

ProAssurance Corporation reported a significant decline in net income and earnings per share for the third quarter and first nine months of 2025, primarily due to increased transaction-related costs for its pending merger with The Doctors Company and higher loss ratios.

Summary

• Net income for the three months ended September 30, 2025, plummeted to $1.4 million ($0.03 diluted EPS) from $16.4 million ($0.32 diluted EPS) in the prior year period.
• For the nine months ended September 30, 2025, net income decreased to $17.5 million ($0.34 diluted EPS) from $36.5 million ($0.71 diluted EPS) in the same period of 2024.
• Consolidated net premiums earned decreased by 4.0% to $233.4 million for the quarter and by 3.5% to $702.1 million for the nine months, driven by reduced participation in Lloyd's Syndicates and proactive profitability actions.
• The combined ratio worsened to 114.7% for the quarter (up 9.1 points) and 111.4% for the nine months (up 2.0 points), indicating a decline in underwriting profitability.
• Net investment income increased by 8.5% to $40.4 million for the quarter and by 8.0% to $116.3 million for the nine months, benefiting from higher average book yields in the current interest rate environment.
• Transaction-related costs for the proposed merger with The Doctors Company amounted to $3.0 million for the quarter and $14.6 million for the nine months.
• Shareholders' equity increased to $1.304 billion as of September 30, 2025, from $1.202 billion at December 31, 2024, primarily due to unrealized holding gains on fixed income investments.
• Book value per share rose to $25.37 at September 30, 2025, from $23.49 at December 31, 2024.

Sentiment

Score: 3

Explanation: The significant decline in net income and EPS, coupled with a worsening combined ratio, indicates poor operational performance. While investment income improved and shareholders' equity increased due to AOCI, the core underwriting results are weak. The pending merger provides a potential floor for the stock price but introduces significant execution risks and costs.

Positives

• Net investment income increased by 8.5% for the quarter and 8.0% for the nine months, driven by higher average book yields.
• Shareholders' equity increased by over $100 million, and book value per share rose by $1.88, largely due to unrealized gains on fixed income investments.
• The allowance for expected credit losses on available-for-sale fixed maturities decreased from $3,399k at December 31, 2024, to $4,031k at September 30, 2025, but unrealized losses on fixed maturities decreased from $227,504k to $144,827k, indicating an improvement in investment portfolio valuation.
• Consolidated net favorable prior year reserve development was $30.0 million for the nine months ended September 30, 2025, reflecting favorable trends in Specialty P&C and Segregated Portfolio Cell Reinsurance segments.
• The Workers' Compensation Insurance segment's current accident year net loss ratio improved by 2.0 percentage points for both the three and nine months ended September 30, 2025, reflecting cost control initiatives.
• The company received a $4.4 million tax refund, including $0.6 million of related interest, in April 2025, stemming from a payroll tax refund claim under the CARES Act.

Negatives

• Net income decreased significantly by 91.2% for the three months and 52.0% for the nine months ended September 30, 2025, compared to the prior year periods.
• Diluted EPS fell from $0.32 to $0.03 for the quarter and from $0.71 to $0.34 for the nine months.
• The consolidated combined ratio worsened to 114.7% for the quarter and 111.4% for the nine months, indicating underwriting losses.
• Net premiums earned decreased across all segments for both the three and nine-month periods, primarily due to discontinued participation in Lloyd's Syndicates and lower written premium volume.
• The Specialty P&C segment's net loss ratio increased by 10.4 points for the quarter and 1.0 point for the nine months, driven by premium adjustments related to loss-sensitive policies and losses from discontinued Lloyd's Syndicates operations.
• Transaction-related costs for the proposed merger totaled $14.6 million for the nine months ended September 30, 2025, impacting profitability.
• Equity in earnings of unconsolidated subsidiaries decreased by 18.6% for the nine months, reflecting lower market valuations during the first half of 2025.
• Foreign currency exchange rate losses had an outsized impact on results, with a $10.0 million loss for the nine months ended September 30, 2025, compared to a $1.4 million loss in the prior year.

Risks

• The proposed merger with The Doctors Company faces numerous risks, including the inability to complete the acquisition on anticipated terms and timing due to pending regulatory approvals in California, Pennsylvania, and Texas.
• Stock price may fluctuate and decline if the proposed merger is not completed.
• Potential litigation related to the proposed transaction could be instituted against the company or its directors, managers, or officers.
• Disruptions from the proposed transaction could harm business, including current plans and operations, and divert management's time and attention.
• Ability to retain and hire key personnel may be impacted by the proposed transaction.
• Potential adverse reactions or changes to business relationships may result from the announcement or completion of the proposed transaction.
• Business uncertainty, including changes to existing business relationships, could affect financial performance during the pendency of the proposed transaction.
• Restrictions during the pendency of the proposed transaction may impact the company's ability to pursue certain business opportunities or strategic transactions.
• The proposed transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events.
• Competitor behavior may change in response to the transaction.
• The occurrence of any event, change, or other circumstance could lead to the termination of the proposed transaction, potentially requiring the company to pay a termination fee.

Future Outlook

The company anticipates closing the merger transaction with The Doctors Company by June 30, 2026, pending remaining regulatory approvals. Management expects further rate increases in the medical professional liability market due to rising loss cost environments. The company also anticipates $90 million to $170 million of its investment portfolio to mature or be paid down each quarter over the next twelve months, providing liquidity. Tax credit partnership investments are reaching the end of their lifecycle, with nominal operating losses and tax benefits expected.

Management Comments

• Management believes the financial statements fairly present in all material respects the financial condition, results of operations, and cash flows.
• Management considers the reserve for losses and loss adjustment expenses, reinsurance, valuation of investments and impairment of securities, and income taxes to be critical accounting estimates involving significant judgment.
• Management evaluates estimates and assumptions on an ongoing basis based on current and historical developments, market conditions, industry trends, and other reasonable information.

Industry Context

The medical professional liability market remains challenging, with physicians increasingly joining hospitals or larger group practices, reducing demand for individual policies. Competitors are often prioritizing market share and investment returns over underwriting profitability. The workers' compensation market also remains competitive, influenced by compounded state loss cost reductions. The current interest rate environment has positively impacted the company's net investment income through higher average book yields, a trend leveraged as the investment portfolio matures.

Corporate Governance

Legal Proceedings

• Involved in various legal actions related to insurance policies and claims handling, which are considered part of the loss reserving process.
• No material reserves established for corporate legal actions as of September 30, 2025.

Related Party Transactions

• Management fees are charged by the Corporate segment to core domestic operating subsidiaries within the Specialty P&C and Workers' Compensation Insurance segments for services provided, based on service extent and gross premium written.
• Premiums in the Segregated Portfolio Cell Reinsurance segment are assumed from the Workers' Compensation Insurance or Specialty P&C segments.

Stakeholder Impact

• Shareholders: Significant decrease in net income and EPS, but an increase in book value per share and a pending merger at a fixed cash price of $25.00 per share, which provides a potential floor for the stock.
• Employees: The proposed merger introduces uncertainty regarding job retention and recruitment of key personnel, and the sale of the legal professional liability business included the transfer of select team members.
• Customers: Proactive actions in certain lines of business to improve profitability and non-renewal of some workers' compensation programs may affect customer relationships and availability of coverage.
• Regulators: Ongoing engagement with insurance regulators for merger approvals in California, Pennsylvania, and Texas, which are critical for transaction completion.
• Creditors: The company remains in compliance with all covenants of its Revolving Credit Agreement, indicating stable debt management.

Next Steps

• Continue to seek regulatory approvals for the proposed merger with The Doctors Company in California, Pennsylvania, and Texas.
• Monitor and manage the integration process and associated costs for the merger, with an anticipated closing by June 30, 2026.
• Implement and evaluate cost control initiatives in the Workers' Compensation Insurance segment.
• Adjust pricing strategies in the Medical Professional Liability market in response to rising loss cost environments.
• Manage the investment portfolio to take advantage of the current interest rate environment as maturities occur.
• Evaluate the effect of new accounting standards (ASU 2023-06, ASU 2023-09, ASU 2024-03, ASU 2025-03, ASU 2025-06) on financial statements and disclosures.

Key Dates

Recommendation

The company's operational performance, as evidenced by the significant decline in net income and worsening combined ratio, is concerning. However, the pending acquisition by The Doctors Company at a fixed cash price of $25.00 per share provides a clear valuation point and limits downside risk for current shareholders. The stock's movement will largely be tied to the probability and timing of this merger's completion, rather than near-term operational results. Investors should hold their positions, awaiting the finalization of the acquisition, unless the current market price significantly deviates from the $25.00 merger consideration.

Keywords

ProAssurance, PRA, SEC Filing, 10-Q, Quarterly Report, Insurance, Medical Professional Liability, Workers' Compensation, Merger, The Doctors Company, Underwriting, Net Income, EPS, Combined Ratio, Investment Income, Loss Reserves, Regulatory Approval, Financial Results